Strides Pharma Science Ltd
Strides Pharma Science Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Strides Pharma Science Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY.
As stated in Strides Pharma Science Ltd's Q2 FY27 investor presentation · published 29 Oct 2026. Reported figures, not investment advice.
Based on Strides Pharma Science Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) - Q2FY27 Ex-US Markets Revenue: ₹6,963 million ($74m), up 31% YoY (Page 13) - Q2FY27 US Market Revenue: ₹6,855 million ($73m), up 9% YoY (Pag EBITDA for Q2FY27: ₹2,509m, up 8.4% YoY (Page 4, 14) - EBITDA margin for Q2FY27: 17.6%, down 140 bps YoY (Page 4, 14) - Operational PAT for Q2FY27: ₹1,358m, up 11.5% YoY (Page 4, 14) - Reported
From Strides Pharma Science Ltd's Q2 FY27 earnings-call transcript · updated 29 Oct 2026.
Revenue & Sales Performance
- Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15)
- Q2FY27 Ex-US Markets Revenue: ₹6,963 million ($74m), up 31% YoY (Page 13)
- Q2FY27 US Market Revenue: ₹6,855 million ($73m), up 9% YoY (Page 11)
- H1FY27 Revenue: ₹26,951 million, up 15.1% YoY (Page 5)
- Ex-US Markets surpassed US revenue for the first time in Q2FY27 (Page 7)
- Revenue mix Q2FY27: Ex-US ₹6,963m vs US ₹6,855m (Page 7)
- Outlook: US revenue aspiration of ~$375m shifts beyond FY28; Ex-US acceleration and disciplined US investment to underpin profitable growth (Page 9)
2 more points from Strides Pharma Science Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Strides Pharma Science Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Strides Pharma Science Ltd said on order book & pipeline — free account, 30 seconds.
Strides Pharma Science Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹1.3K Cr, net profit ₹165 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma Science Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
- Aarti Pharmalabs Ltd (Q2 FY27)
19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Strides Pharma Science Ltd Q2 FY27 results?
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) - Q2FY27 Ex-US Markets Revenue: ₹6,963 million ($74m), up 31% YoY (Page 13) - Q2FY27 US Market Revenue: ₹6,855 million ($73m), up 9% YoY (Pag EBITDA for Q2FY27: ₹2,509m, up 8.4% YoY (Page 4, 14) - EBITDA margin for Q2FY27: 17.6%, down 140 bps YoY (Page 4, 14) - Operational PAT for Q2FY27: ₹1,358m, up 11.5% YoY (Page 4, 14) - Reported
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a neutral. The stock trades at a P/E of 17.5 with a market cap of ₹10,120 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.